Amyloid accomplices and enforcers

Protein Science

Volumn 14, Issue 1, 2005, Pages 1-12

  Alexandrescu, Andrei T ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Alzheimer A peptide; Basal lamina; Extracellular matrix proteins; Heparan sulfate proteoglycans; Protein folding

Indexed keywords

AGRIN; AMYLIN; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID P COMPONENT; AMYLOID P COMPONENT INHIBITOR; ANTIBODY; APOLIPOPROTEIN E; CHAPERONE; CHELATING AGENT; CLIOQUINIL; ENZYME INHIBITOR; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; INSULIN; LAMININ; METAL DERIVATIVE; METHYL 4,6 O (1 CARBOXYETHYLIDENE) BETA DEXTRO GALACTOPYRANOSIDE; PERLECAN; PRION PROTEIN; PROTEOHEPARAN SULFATE; RNA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BASEMENT MEMBRANE; CHOLESTEROL METABOLISM; DIAGNOSTIC TEST; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; SIDE EFFECT; TOXICITY;

AMYLOID; GLYCOSAMINOGLYCANS; HUMANS; MOLECULAR CHAPERONES; PROTEIN FOLDING; PROTEINS; PROTEOGLYCANS;

EID: 11144221004     PISSN: 09618368     EISSN: None     Source Type: Journal    
DOI: 10.1110/ps.04887005     Document Type: Review

References (122)

1. Adjou, K.T., Simoneau, S., Sales, N., Lamoury, F., Dormont, D., Papy-Garcia, D., Barritault, D., Deslys, J.P., and Lasmezas, C.I. 2003. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J. Gen. Virol. 84: 2595-2603.
2. Alexandrescu, A.T. 2001. An NMR-based quenched hydrogen exchange investigation of model amyloid fibrils formed by cold shock protein A. Pac. Symp. Biocomput. 67-78.
3. Alexandrescu, A.T. and Rathgeb-Szabo, K. 1999. An NMR investigation of solution aggregation reactions preceding the misassembly of acid-denatured cold shock protein A into fibrils. J. Mol. Biol. 291: 1191-1206.
4. Ancsin, J.B. 2003. Amyloidogenesis: Historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid 10: 67-79.
5. Ancsin, J.B. and Kisilevsky, R. 1999. The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J. Biol. Chem. 274: 7172-7181.
6. Anfinsen, C.B. 1973. Principles that govern the folding of protein chains. Science 181: 223-230.
7. Bacskai, B.J., Hickey, G.A., Skoch, J., Kajdasz, S.T., Wang, Y., Huang, G.F., Mathis, C.A., Klunk, W.E., and Hyman, B.T. 2003. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-β ligand in transgenic mice. Proc. Natl. Acad. Sci. 100: 12462-12467.
8. Bales, K.R., Dodart, J.C., DeMattos, R.B., Holtzman, D.M., and Paul, S.M. 2002. Apolipoprotein E, amyloid, and Alzheimer disease. Mol. Intervent. 2: 363-375.
9. Bame, K.J., Danda, J., Hassall, A., and Tumova, S. 1997. Aβ(1-40) prevents heparanase-catalyzed degradation of heparan sulfate glycosaminoglycans and proteoglycans in vitro. A role for heparan sulfate proteoglycan turnover in Alzheimer's disease. J. Biol. Chem. 272: 17005-17011.
10. Barnham, K.J., McKinstry, W.J., Multhaup, G., Galatis, D., Morton, C.J., Curtain, C.C., Williamson, N.A., White, A.R., Hinds, M.G., Norton, R.S., et al. 2003. Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J. Biol. Chem. 278: 17401-17407.
11. Bezakova, G. and Ruegg, M.A. 2003. New insights into the roles of agrin. Nat. Rev. Mol. Cell Biol. 4: 295-308.
12. Booth, D.R., Sunde, M., Bellotti, V., Robinson, C.V., Hutchinson, W.L., Fraser, P.E., Hawkins, P.N., Dobson, C.M., Radford, S.E., Blake, C.C., et al. 1997. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis. Nature 385: 787-793.
13. Bosman, F.T. and Stamenkovic, I. 2003. Functional structure and composition of the extracellular matrix. J. Pathol. 200: 423-428.
14. Brown, J.C., Sasaki, T., Gohring, W., Yamada, Y., and Timpl, R. 1997. The C-terminal domain V of perlecan promotes β1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans. Eur. J. Biochem. 250: 39-46.
15. Burgess, R.W., Dickman, D.K., Nunez, L., Glass, D.J., and Sanes, J.R. 2002. Mapping sites responsible for interactions of agrin with neurons. J. Neurochem. 83: 271-284.
16. Bush, A.I. 2002. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol. Aging 23: 1031-1038.
17. -. 2003. The metallobiology of Alzheimer's disease. Trends Neurosci. 26: 207-214.
18. Bush, A.I. and Tanzi, R.E. 2002. The galvanization of β-amyloid in Alzheimer's disease. Proc. Natl. Acad. Sci. 99: 7317-7319.
19. Bush, A.I., Pettingell, W.H., Multhaup, G., d Paradis, M., Vonsattel, J.P., Gusella, J.F., Beyreuther, K., Masters, C.L., and Tanzi, R.E. 1994. Rapid induction of Alzheimer A β amyloid formation by zinc. Science 265: 1464-1467.
20. Cardin, A.D. and Weintraub, H.J. 1989. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9: 21-32.
21. Castillo, G.M., Ngo, C., Cummings, J., Wight, T.N., and Snow, A.D. 1997. Perlecan binds to the β-amyloid proteins (A β) of Alzheimer's disease, accelerates A β fibril formation, and maintains A β fibril stability. J. Neurochem. 69: 2452-2465.
22. Castillo, G.M., Cummings, J.A., Yang, W., Judge, M.E., Sheardown, M.J., Rimvall, K., Hansen, J.B., and Snow, A.D. 1998. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation. Diabetes 47: 612-620.
23. Castillo, G.M., Lukito, W., Wight, T.N., and Snow, A.D. 1999. The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation. J. Neurochem. 72: 1681-1687.
24. Castillo, G.M., Lukito, W., Peskind, E., Raskind, M., Kirschner, D.A., Yee, A.G., and Snow, A.D. 2000. Laminin inhibition of β-amyloid protein (Aβ) fibrillogenesis and identification of an Aβ binding site localized to the globular domain repeats on the laminin a chain. J. Neurosci. Res. 62: 451-462.
25. Cherny, R.A., Legg, J.T., McLean, C.A., Fairlie, D.P., Huang, X., Atwood, C.S., Beyreuther, K., Tanzi, R.E., Masters, C.L., and Bush, A.I. 1999. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J. Biol. Chem. 274: 23223-23228.
26. Chiti, F., Taddei, N., Bucciantini, M., White, P., Ramponi, G., und Dobson, C.M. 2000. Mutational analysis of the propensity for amyloid formation by a globular protein. EMBO J. 19: 1441-1449.
27. Cohlberg, J.A., Li, J., Uversky, V.N., and Fink, A.L. 2002. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry 41: 1502-1511.
28. Coker, A.R., Purvis, A., Baker, D., Pepys, M.B., and Wood, S.P. 2000. Molecular chaperone properties of serum amyloid P component. FEBS Lett. 473: 199-202.
29. Cotman, S.L., Halfter, W., and Cole, G.J. 2000. Agrin binds to β-amyloid (Aβ), accelerates aβ fibril formation, and is localized to Aβ deposits in Alzheimer's disease brain. Mol. Cell. Neurosci. 15: 183-198.
30. Dawson, P.E. and Kent, S.B. 2000. Synthesis of native proteins by chemical ligation. Annu. Rev. Biochem. 69: 923-960.
31. Deleault, N.R., Lucassen, R.W., and Supattapone, S. 2003. RNA molecules stimulate prion protein conversion. Nature 425: 717-720.
32. DeMattos, R.B., Bales, K.R., Cummins, D.J., Paul, S.M., and Holtzman, D.M. 2002a. Brain to plasma amyloid-β efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295: 2264-2267.
33. DeMattos, R.B., O'Dell, M.A., Parsadanian, M., Taylor, J.W., Harmony, J.A., Bales, K.R., Paul, S.M., Aronow, B.J., and Holtzman, D.M. 2002b. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. 99: 10843-10848.
34. Dobson, C.M. 1999. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24: 329-332.
35. -. 2002. Protein misfolding and human disease. Sci. World J. 2: 132.
36. -. 2003. Protein folding and misfolding. Nature 426: 884-890.
37. Donahue, J.E., Berzin, T.M., Rafii, M.S., Glass, D.J., Yancopoulos, G.D., Fallon, J.R., and Stopa, E.G. 1999. Agrin in Alzheimer's disease: Altered solubility and abnormal distribution within microvasculature and brain parenchyma. Proc. Natl. Acad. Sci. 96: 6468-6472.
38. Dunker, A.K. and Obradovic, Z. 2001. The protein trinity - Linking function and disorder. Nat. Biotechnol. 19: 805-806.
39. Emsley, J., White, H.E., O'Hara, B.P., Oliva, G., Srinivasan, N., Tickle, I.J., Blundell, T.L., Pepys, M.B., and Wood, S.P. 1994. Structure of pentameric human serum amyloid P component. Nature 367: 338-345.
40. Engel, J. 1992. Laminins and other strange proteins. Biochemistry 31: 10643-10651.
41. Fandrich, M., Fletcher, M.A., and Dobson, C.M. 2001. Amyloid fibrils from muscle myoglobin. Nature 410: 165-166.
42. Fraser, P.E., Nguyen, J.T., Chin, D.T., and Kirschner, D.A. 1992. Effects of sulfate ions on Alzheimer β/A4 peptide assemblies: Implications for amyloid fibril-proteoglycan interactions. J. Neurochem. 59: 1531-1540.
43. Fukuchi, K., Hart, M., and Li, L. 1998. Alzheimer's disease and heparan sulfate proteoglycan. Front. Biosci. 3: d327-d337.
44. Garbe, J.H., Gohring, W., Mann, K., Timpl, R., and Sasaki, T. 2002. Complete sequence, recombinant analysis and binding to laminins and sulphated ligands of the N-terminal domains of laminin α3B and α5 chains. Biochem. J. 362: 213-221.
45. Garret, R.H. and Grisham, C.M. 1999. Biochemistry, 2nd ed. Saunders, New York.
46. Gewurz, H., Zhang, X.H., and Lint, T.F. 1995. Structure and function of the pentraxins. Curr. Opin. Immunol. 7: 54-64.
47. Goedert, M., Jakes, R., Spillantini, M.G., Hasegawa, M., Smith, M.J., and Crowther, R.A. 1996. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383: 550-553.
48. Gupta-Bansal, R., Frederickson, R.C., and Brunden, K.R. 1995. Proteoglycan-mediated inhibition of A β proteolysis. A potential cause of senile plaque accumulation. J. Biol. Chem. 270: 18666-18671.
49. Gurwitz, D. 2000. New imaging techniques for early diagnosis of Alzheimer's disease. Mol. Med. Today 6: 340.
50. 2+-mediated association of human serum amyloid P component with heparan sulfate and dermatan sulfate. J. Biol. Chem. 262: 1456-1460.
51. -. 1995. Ca(2+)-dependent binding of human serum amyloid P component to Alzheimer's β-amyloid peptide. J. Biol. Chem. 270: 10392-10394.
52. Hartmann, U. and Maurer, P. 2001. Proteoglycans in the nervous system - The quest for functional roles in vivo. Matrix Biol. 20: 23-35.
53. Hind, C.R., Collins, P.M., Caspi, D., Baltz, M.L., and Pepys, M.B. 1984. Specific chemical dissociation of fibrillar and non-fibrillar components of amyloid deposits. Lancet 2: 376-378.
54. Hirschfield, G.M. and Hawkins, P.N. 2003. Amyloidosis: New strategies for treatment. Int. J. Biochem. Cell Biol. 35: 1608-1613.
55. Hohenester, E. and Engel, J. 2002. Domain structure and organisation in extracellular matrix proteins. Matrix Biol. 21: 115-128.
56. Holtzman, D.M. 2003. Potential role of endogenous and exogenous amyloid-P binding molecules in the pathogenesis, diagnosis, and treatment of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 17: 151-153.
57. Huang, T.H.J., Fraser, P.E., and Chakrabartty, A. 1997. Fibrillogenesis of Alzheimer Aβ peptides studied by fluorescence energy transfer. J. Mol. Biol. 269: 214-224.
58. Huang, X., Atwood, C.S., Hartshorn, M.A., Multhaup, G., Goldstein, L.E., Scarpa, R.C., Cuajungco, M.P., Gray, D.N., Lim, J., Moir, R.D., et al. 1999. The A β peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 38: 7609-7616.
59. Hughes, S.R., Khorkova, O., Goyal, S., Knaeblein, J., Heroux, J., Riedel, N.G., and Sahasrabudhe, S. 1998. α2-macroglobulin associates with β-amyloid peptide and prevents fibril formation. Proc. Natl. Acad. Sci. 95: 3275-3280.
60. Inoue, S. and Kisilevsky, R. 1999. In situ electron microscopy of amyloid deposits in tissues. Methods Enzymol. 309: 496-509.
61. Inoue, S., Hultin, P.G., Szarek, W.A., and Kisilevsky, R. 1996. Effect of poly(vinylsulfonate) on murine AA amyloid: A high-resolution ultrastructural study. Lab. Invest. 74: 1081-1090.
62. Inoue, S., Kuroiwa, M., Ohashi, K., Hara, M., and Kisilevsky, R. 1997. Ultrastructural organization of hemodialysis-associated β 2-microglobulin amyloid fibrils. Kidney Int. 52: 1543-1549.
63. Jaikaran, E.T., Nilsson, M.R., and Clark, A. 2004. Pancreatic β-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem. J. 377: 709-716.
64. Jiang, X. and Couchman, J.R. 2003. Perlecan and tumor angiogenesis. J. Histochem. Cytochem. 51: 1393-1410.
65. Jobling, M.F., Huang, X., Stewart, L.R., Barnham, K.J., Curtain, C., Volitakis, I., Perugini, M., White, A.R., Cherny, R.A., Masters, C.L., et al. 2001. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Biochemistry 40: 8073-8084.
66. Khan, A.A., Bose, C., Yam, L.S., Soloski, M.J., and Rupp, F. 2001. Physiological regulation of the immunological synapse by agrin. Science 292: 1681-1686.
67. Kisilevsky, R. 2000. Review: Amyloidogenesis-Unquestioned answers and unanswered questions. J. Struct. Biol. 130: 99-108.
68. Kiselevsky, R., Szarek, W.A., Ancsin, J., Bhat, S., Li, Z., and Marone, S. 2003. Novel glycosaminoglycan precursors as anti-amyloid agents, Part III. J. Mol. Neurosci. 20: 291-297.
69. Kiuchi, Y., Isobe, Y., Fukushima, K., and Kimura, M. 2002. Disassembly of amyloid β-protein fibril by basement membrane components. Life Sci. 70: 2421-2431.
70. Larson, J.L. and Miranker, A.D. 2004. The mechanism of insulin action on islet amyloid polypeptide fiber formation. J. Mol. Biol. 335: 221-231.
71. Lee, V.M.-Y. 2002. Amyloid binding ligands as Alzheimer's disease therapies. Neurobiol. Aging 23: 1039-1042.
72. Lee, J.Y., Cole, T.B., Palmiter, R.D., Suh, S.W., and Koh, J.Y. 2002. Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl. Acad. Sci. 99: 7705-7710.
73. Libeu, C.P., Lund-Katz, S., Phillips, M.C., Wehrli, S., Hemaiz, M.J., Capila, I., Linhardt, R.J., Raffai, R.L., Newhouse, Y.M., Zhou, F., et al. 2001. New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. J. Biol. Chem. 276: 39138-39144.
74. Liu, S.T., Howlett, G., and Barrow, C.J. 1999. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A β peptide of Alzheimer's disease. Biochemistry 38: 9373-9378.
75. Lopez De La Paz, M., Goldie, K., Zurdo, J., Lacroix, E., Dobson, C.M., Hoenger, A., and Serrano, L. 2002. De novo designed peptide-based amyloid fibrils. Proc. Natl. Acad. Sci. 99: 16052-16057.
76. Lukacs, C.M. and Christianson, D.W. 1996. Is the binding of β-amyloid protein to antichymotrypsin in Alzheimer plaques mediated by a β-strand insertion? Proteins 25: 420-424.
77. Maggio, J.E., Stimson, E.R., Ghilardi, J.R., Allen, C.J., Dahl, C.E., Whitcomb, D.C., Vigna, S.R., Vinters, H.V., Labenski, M.E., and Mantyh, P.W. 1992. Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide. Proc. Natl. Acad. Sci. 89: 5462-5466.
78. Matsuoka, Y., Saito, M., LaFrancois, J., Saito, M., Gaynor, K., Olm, V., Wang, L., Casey, E., Lu, Y., Shiratori, C., et al. 2003. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J. Neurosci. 23: 29-33.
79. Maynard, C.J., Cappai, R., Volitakis, I., Cherny, R.A., White, A.R., Beyreuther, K., Masters, C.L., Bush, A.I., and Li, Q.X. 2002. Overexpression of Alzheimer's disease amyloid-β opposes the age-dependent elevations of brain copper and iron. J. Biol. Chem. 277: 44670-44676.
80. Miura, T., Suzuki, K., Kohata, N., and Takeuchi, H. 2000. Metal binding modes of Alzheimer's amyloid β-peptide in insoluble aggregates and soluble complexes. Biochemistry 39: 7024-7031.
81. Morgan, C.J., Gelfand, M., Atreya, C., and Miranker, A.D. 2001. Kidney dialysis-associated amyloidosis: A molecular role for copper in fiber formation. J. Mol. Biol. 309: 339-345.
82. Morgan, C., Bugueno, M.P., Garrido, J., and Inestrosa, N.C. 2002. Laminin affects polymerization, depolymerization and neurotoxicity of Aβ peptide. Peptides 23: 1229-1240.
83. Ohashi, K., Kisilevsky, R., and Yanagishita, M. 2002. Affinity binding of glycosaminoglycans with β(2)-microglobulin. Nephron 90: 158-168.
84. Paul, E. and Carroll, M.C. 1999. SAP-less chromatin triggers systemic lupus erythematosus. Nat. Med. 5: 607-608.
85. Pepys, M.B. 2001. Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos. Trans. R. Soc. Lond. B 356: 203-211.
86. Pepys, M.B., Rademacher, T.W., Amatayakul-Chantler, S., Williams, P., Noble, G.E., Hutchinson, W.L., Hawkins, P.N., Nelson, S.R., Gallimore, J.R., Herbert, J., et al. 1994. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc. Natl. Acad. Sci. 91: 5602-5606.
87. Pepys, M.B., Herbert, J., Hutchinson, W.L., Tennent, G.A., Lachmann, H.J., Gallimore, J.R., Lovat, L.B., Bartfai, T., Alanine, A., Hertel, C., et al. 2002. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417: 254-259.
88. Potter-Perigo, S., Hull, R.L., Tsoi, C., Braun, K.R., Andrikopoulos, S., Teague, J., Bruce Verchere, C., Kahn, S.E., and Wight, T.N. 2003. Proteoglycans synthesized and secreted by pancreatic islet β-cells bind amylin. Arch. Biochem. Biophys. 413: 182-190.
89. Rochet, J.C. and Lansbury Jr., P.T. 2000. Amyloid fibrillogenesis: Themes and variations. Curr. Opin. Struct. Biol. 10: 60-68.
90. Rogers, J.T., Randall, J.D., Cahill, C.M., Eder, P.S., Huang, X., Gunshin, H., Leiter, L., McPhee, J., Sarang, S.S., Utsuki, T., et al. 2002. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277: 45518-45528.
91. Rossjohn, J., Cappai, R., Feil, S.C., Henry, A., McKinstry, W.J., Galatis, D., Hesse, L., Multhaup, G., Beyreuther, K., Masters, C.L., et al. 1999. Crystal structure of the N-terminal growth factor-like domain of Alzheimer amyloid precursor protein. Nat. Struct. Biol. 6: 327-331.
92. Rudenko, G., Hohenester, E., and Muller, Y.A. 2001. LG/LNS domains: Multiple functions-One business end? Trends Biochem. Sci. 26: 363-368.
93. Sanes, J.R. and Lichtman, J.W. 2001. Induction, assembly, maturation and maintenance of a postsynaptic apparatus. Nat. Rev. Neurosci. 2: 791-805.
94. Sasaki, T., Costell, M., Mann, K., and Timpl, R. 1998. Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity. FEBS Lett. 435: 169-172.
95. Sasaki, T., Fassler, R., and Hohenester, E. 2004. Laminin: The crux of basement membrane assembly. J. Cell Biol. 164: 959-963.
96. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
97. Sipe, J.D. 1992. Amyloidosis. Annu. Rev. Biochem. 61: 947-975.
98. Snow, A.D. and Wight, T.N. 1989. Proteoglycans in the pathogenesis of Alzheimer's disease and other amyloidoses. Neurobiol. Aging 10: 481-497.
99. Snow, A.D., Sekiguchi, R., Nochlin, D., Fraser, P., Kimata, K., Mizutani, A., Arai, M., Schreier, W.A., and Morgan, D.G. 1994. An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A β-amyloid in rat brain. Neuron 12: 219-234.
100. Snow, A.D., Kinsella, M.G., Parks, E., Sekiguchi, R.T., Miller, J.D., Kimata, K., and Wight, T.N. 1995. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the β-amyloid protein of Alzheimer's disease. Arch. Biochem. Biophys. 320: 84-95.
101. 2+ binding. Structure (Camb.) 12: 503-515.
102. Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y., Dong, L.-M., Salvesen, G.S., Pericak-Vance, M., Schmechel, D., Saunders, A.M., Goldgaber, D., and Roses, A.D. 1993. Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. 90: 8098-8102.
103. Supattapone, S. 2004. Prion protein conversion in vitro. J. Mol. Med. 82: 348-356.
104. Talts, J.F., Andac, Z., Gohring, W., Brancaccio, A., and Timpl, R. 1999. Binding of the G domains of laminin α1 and α2 chains and perlecan to heparin, sulfatides, α-dystroglycan and several extracellular matrix proteins. EMBO J. 18: 863-870.
105. Tennent, G.A., Lovat, L.B., and Pepys, M.B. 1995. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. 92: 4299-4303.
106. Thompson, D., Pepys, M.B., Tickle, I., and Wood, S. 2002. The structures of crystalline complexes of human serum amyloid P component with its carbohydrate ligand, the cyclic pyruvate acetal of galactose. J. Mol. Biol. 320: 1081-1086.
107. Uversky, V.N., Li, J., and Fink, A.L. 2001. Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276: 44284-44296.
108. van Horssen, J., Otte-Holler, I., David, G., Maat-Schieman, M.L., van den Heuvel, L.P., Wesseling, P., de Waal, R.M., and Verbeek, M.M. 2001. Heparan sulfate proteoglycan expression in cerebrovascular amyloid β deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol. (Berl.) 102: 604-614.
109. van Horssen, J., Kleinnijenhuis, J., Maass, C.N., Rensink, A.A., Otte-Holler, I., David, G., van den Heuvel, L.P., Wesseling, P., de Waal, R.M., and Verbeek, M.M. 2002. Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. Neurobiol. Aging 23: 537-545.
110. Verbeek, M.M., Otte-Holler, I., van den Born, J., van den Heuvel, L.P., David, G., Wesseling, P., and de Waal, R.M. 1999. Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. Am. J. Pathol. 155: 2115-2125.
111. Wadsworth, J.D., Hill, A.F., Joiner, S., Jackson, G.S., Clarke, A.R., and Collinge, J. 1999. Strain-specific prion-protein conformation determined by metal ions. Nat. Cell Biol. 1: 55-59.
112. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J., and Selkoe, D.J. 2002. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
113. Wang, Y. and Ha, Y. 2004. The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain. Mol. Cell 15: 345-353.
114. Wang, H.Y., Lee, D.H., Davis, C.B., and Shank, R.P. 2000. Amyloid peptide Aβ(1-42) binds selectively and with picomolar affinity to α7 nicotinic acetylcholine receptors. J. Neurochem. 75: 1155-1161.
115. Watson, D.J., Lander, A.D., and Selkoe, D.J. 1997. Heparin-binding properties of the amyloidogenic peptides Aβ and amylin. Dependence on aggregation state and inhibition by Congo red. J. Biol. Chem. 272: 31617-31624.
116. Watt, N.T. and Hooper, N.M. 2003. The prion protein and neuronal zinc homeostasis. Trends Biochem. Sci. 28: 406-410.
117. Yaar, M., Zhai, S., Pilch, P.F., Doyle, S.M., Eisenhauer, P.B., Fine, R.E., and Gilchrest, B.A. 1997. Binding of β-amyloid to the p75 neurotrophin receptor induces apoptosis. A possible mechanism for Alzheimer's disease. J. Clin. Invest. 100: 2333-2340.
118. Yamaguchi, I., Suda, H., Tsuzuike, N., Seto, K., Seki, M., Yamaguchi, Y., Hasegawa, K., Takahashi, N., Yamamoto, S., Gejyo, F., et al. 2003. Glycosaminoglycan and proteoglycan inhibit the depolymerization of β2-microglobulin amyloid fibrils in vitro. Kidney Int. 64: 1080-1088.
119. Yamashita, H., Beck, K., and Kitagawa, Y. 2004. Heparin binds to the laminin α4 chain LG4 domain at a site different from that found for other laminins. J. Mol. Biol. 335: 1145-1149.
120. Yurchenco, P.D., Amenta, P.S., and Patton, B.L. 2004. Basement membrane assembly, stability and activities observed through a developmental lens. Matrix Biol. 22: 521-538.
121. Zahedi, K. 1997. Characterization of the binding of serum amyloid P to laminin. J. Biol. Chem. 272: 2143-2148.
122. Zhang, Q., Powers, E.T., Nieva, J., Huff, M.E., Dendle, M.A., Bieshke, J., Glabe, C.G., Eschenmoser, A., Wentworth Jr., P., Lerner, R.A., et al. 2004. Metabolite-initiated protein misfolding may trigger Alzheimer's disease. Proc. Natl. Acad. Sci. 101: 4752-4757.